Live Breaking News & Updates on Clinical Development Of Innovent

Stay updated with breaking news from Clinical development of innovent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes. ....

United-states , Suzhou , Jiangsu , China , Peking , Beijing , American , Chinese , Adimab-incyte , Innovent-biologics , Eli-lilly , Linong-ji

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all. ....

Suzhou , Jiangsu , China , Shanghai , Yulin-shi , Shaanxi , Chinese , Eli-lilly , Adimab-incyte , Innovent-biologics , National-medical-product-administration , Prnewswire-innovent-biologics-inc

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | Taiwan News

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | Taiwan News
taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.

Shanghai , China , Yulin-shi , Shaanxi , Suzhou , Jiangsu , Chinese , Eli-lilly , Adimab-incyte , Innovent-biologics , Md-anderson-cancer-center , Linkedin

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

/PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes. ....

China , Minnesota , United-states , Suzhou , Jiangsu , Jiaotong , Guizhou , Xianqun , Qinghai , Shanghai , American , Chinese

Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints

Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Japan , Suzhou , Jiangsu , China , Beijing , Chinese , Innovent-biologics , Yang-wenying , Lixin-guo , Eli-lilly , Adimab-incyte , Department-of-endocrinology